XERS (Xeris Pharma) Multiplikator Forward P/S

Lambang korporat lan logo Xeris Biopharma (XERS)

Complex pharmaceutical logistics and insurer pressure on margins within a narrow product portfolio create volatility for Xeris Biopharma (XERS). The forward revenue multiple visualizes these market expectations, where 8.20 represents the current metric. Meanwhile, geopolitical threats and trade conflicts have virtually no impact on the business, as production is localized in stable markets.

Xeris Biopharma Holdings - Multiplikator Forward P/S XERS (periode 04.07.2022 - 15.11.2026)

Ringkesan rincian data analitis Xeris Biopharma (XERS)

Analisis fundamental perusahaan:Xeris Biopharma (XERS)
Produk asli Xeris Pharma

Revenue growth from Gvoke and Recorlev sales drives the market value of Xeris Biopharma (XERS). The company's modeled P/S ratio compares the current quote with projected sales volume, measuring the premium the market is willing to pay for future revenue streams. The price action of the company's modeled P/S reveals price deviations from fundamental expectations regarding XeriSol licensing. High indicator values signal overvaluation and risks of a capital correction.

Analisis pesaing Xeris Biopharma

Rasio rega marang prakiraan pendapatan Vertex VRTX|ALNY (Alnylam Inc.) - Rega mangsa ngarep marang pendapatan|Insmed Incorporated - Multiplikator Forward P/S|Rega forward marang dodolan UTHR (United Therapeutics)|BMRN: Multiplikator Forward P/S|BridgeBio Pharma (BBIO) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan bgm.ltd|COGT: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan kerostx.com (KROS)|Multiplikator forward rega marang pendapatan Arcturus Therapeutics ARCT|Multiplikator Forward P/S ETON (etonpharma.com)|Multiplikator Forward P/S Kamada Ltd KMDA|Fulcrum Therapeutics, Inc. - Multiplikator Forward P/S|ABEO - Multiplikator Forward P/S|MREO: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Protalix BioTherapeutics, Inc. (PLX)|PLRX (Pliant Therapeutics, Inc.) - Multiplikator Forward P/S|Applied Therapeutics Inc. - Rega mangsa ngarep marang pendapatan|Rasio rega marang prakiraan pendapatan Rein Therapeutics Inc (RNTX)|Rasio rega marang pendapatan sing dikarepake GELS|Aytu BioPharma, Inc. - Multiplikator forward rega marang pendapatan|Chemomab Therapeutics (CMMB) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|SRx Health - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Polyrizon Limited PLRZ|AEZS: Multiplikator Forward P/S|CYTH: Rasio rega marang pendapatan sing dikarepake|Multiplikator forward rega marang pendapatan INZY|RPHM: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan CSCI (COSCIENS Biopharma)